After a bright start to the year, biotechnology stocks have found themselves on the wrong end of a hiding. The SPDR S&P Biotech Index ETF (XBI) currently trades near where it began the year, after gaining 30% at its high in February. The speculative furor has eased, but what have been some of the contributing factors to the losses from March?
Hey, check out all the research scientist jobs. Post your resume today!
